CytomX’s CX-801 Enters Key Early Cancer Trial Phase, Putting CTMX Back on Investor Radar
CytomX Therapeutics (CTMX) announced that its experimental cancer drug, CX-801, has entered a key early-phase clinical trial (CTMX-801-101) for advanced solid tumors. The study, conducted alone and in combination with Merck's Keytruda, aims to assess safety, dosage, and initial anti-tumor activity. This development emphasizes CytomX's strategic focus on the solid tumor market and could significantly influence investor sentiment as trial data emerges.
APR 25·MarketBeat▼
Wall Street Zen Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Strong Sell
Wall Street Zen has downgraded CytomX Therapeutics (NASDAQ:CTMX) from "sell" to "strong sell" following the company's Q1 earnings miss and significant insider stock sales. Despite this, the broader analyst community maintains a "Moderate Buy" consensus with a higher average price target, suggesting a divergence in outlooks. The report highlights CTMX's recent financial performance, insider activity, and institutional ownership, contrasting it with other analysts' more optimistic ratings and price targets.
MAR 27·Stock Titan→
Vanguard (CTMX) reports 0 shares; disaggregation after internal realignment
The Vanguard Group filed an amended Schedule 13G/A, reporting 0 shares and 0% beneficial ownership of CytomX Therapeutics Inc (CTMX) common stock as of March 13, 2026. This change is due to an internal realignment on January 12, 2026, where Vanguard's subsidiaries began reporting beneficial ownership separately, as permitted by SEC Release No. 34-39538. The filing indicates no voting or dispositive power over CTMX shares for The Vanguard Group itself.
